Journal of Emergency Health Care
Formerly known as: International Journal of Medical Investigation
Volume 13, Issue 4 (12-2024)
J Emerg Health Care 2024, 13(4): 192-201 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Pournouri A, Asadi M. The Role of YKL-40 and Dipeptidyl Peptidase-4 in Asthma: A Narrative Review. J Emerg Health Care 2024; 13 (4) :192-201
URL: http://intjmi.com/article-1-1211-en.html
URL: http://intjmi.com/article-1-1211-en.html
Research committee of Dezful University of Medical Sciences, Dezful, Iran
Abstract: (330 Views)
Background: Asthma is a complex and heterogeneous disease characterized by chronic inflammation, airway remodeling, and variable clinical manifestations. Despite advances in asthma management, there is a need for novel biomarkers to improve diagnosis, predict disease severity, and monitor treatment responses.
Objective: To review the current evidence on the role of YKL-40 and dipeptidyl peptidase-4 (DPP-4) in asthma, including their potential as biomarkers for disease severity, treatment responses, and genetic predisposition.
Methods: A comprehensive literature search was conducted to identify studies investigating the relationship between YKL-40, DPP-4, and asthma. Relevant articles were selected based on their relevance to the topic and study design.
Results: The review highlights the association of YKL-40 with airway remodeling, inflammation, and disease severity in asthma. Elevated YKL-40 levels have been linked to poor prognosis, increased exacerbations, and reduced lung function. Genetic variations in the CHI3L1 gene, which encodes YKL-40, have been associated with asthma susceptibility and severity. DPP-4 has been implicated in the regulation of inflammation and immune responses in asthma, with studies suggesting its potential role in modulating airway inflammation and remodeling.
Conclusion: YKL-40 and DPP-4 are promising biomarkers for asthma, with potential applications in disease diagnosis, severity assessment, and treatment monitoring. Further research is needed to fully elucidate their roles in asthma pathophysiology and to explore their clinical utility in asthma management.
Objective: To review the current evidence on the role of YKL-40 and dipeptidyl peptidase-4 (DPP-4) in asthma, including their potential as biomarkers for disease severity, treatment responses, and genetic predisposition.
Methods: A comprehensive literature search was conducted to identify studies investigating the relationship between YKL-40, DPP-4, and asthma. Relevant articles were selected based on their relevance to the topic and study design.
Results: The review highlights the association of YKL-40 with airway remodeling, inflammation, and disease severity in asthma. Elevated YKL-40 levels have been linked to poor prognosis, increased exacerbations, and reduced lung function. Genetic variations in the CHI3L1 gene, which encodes YKL-40, have been associated with asthma susceptibility and severity. DPP-4 has been implicated in the regulation of inflammation and immune responses in asthma, with studies suggesting its potential role in modulating airway inflammation and remodeling.
Conclusion: YKL-40 and DPP-4 are promising biomarkers for asthma, with potential applications in disease diagnosis, severity assessment, and treatment monitoring. Further research is needed to fully elucidate their roles in asthma pathophysiology and to explore their clinical utility in asthma management.
Keywords: Asthma, YKL-40, Dipeptidyl Peptidase-4, Biomarkers, Airway Remodeling, Inflammation, Genetic Predisposition, Disease Severity, Treatment Responses.
References
1. 1. Ojo RO, Okobi OE, Ezeamii PC, Ezeamii VC, Nwachukwu EU, Gebeyehu YH, Okobi E, David AB, Akinsola Z. Epidemiology of Current Asthma in Children Under 18: A Two-Decade Overview Using National Center for Health Statistics (NCHS) Data. Cureus. 2023 Nov;15(11).
2. Jiang Y, Yue Q, An R, Tie Z, Liu Y, Yu L, Kong X. A systematic review and meta-analysis of the prevalence and epidemiology of asthma in people over 14 years of age in China. Journal of Asthma. 2023 Nov 2;60(11):1960-6.
3. Frey SM, Rowe RK, Halterman JS. The prevalence of childhood asthma: interpreting falling rates in the context of shifting measurement and the COVID-19 pandemic. Current Opinion in Pulmonary Medicine. 2023 May 1;29(3):197-201.
4. Rakhshanda S, Abedin M, Wahab A, Barua L, Faruque M, Banik PC, Shawon RA, Rahman AF, Mashreky SR. Self-reported prevalence of asthma and its associated factors among adult rural population in Bangladesh: a cross-sectional study using WHO PEN protocol. BMJ open. 2023 Dec 1;13(12):e074195.
5. National Heart Lung and Blood Institute. Global initiative for asthma: global strategy for asthma management and prevention. InNHLBI/WHO workshop report. NHLBI publication 1995.
6. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004 May;59(5):469-78.
7. Busse WW, Castro M, Casale TB. Asthma management in adults. The Journal of Allergy and Clinical Immunology: In Practice. 2023 Jan 1;11(1):21-33.
8. Mosbech CH, Godtfredsen NS, Ulrik CS, Westergaard CG. Biomarker-guided withdrawal of inhaled corticosteroids in asthma patients with a non-T2 inflammatory phenotype–a randomized controlled trial study protocol. BMC Pulmonary Medicine. 2023 Oct 4;23(1):372.
9. Huang J, Pansare M. New treatments for asthma. Immunology and Allergy Clinics. 2021 Nov 1;41(4):555-69.
10. Eastwood MC, Busby J, Jackson DJ, Pavord ID, Hanratty CE, Djukanovic R, Woodcock A, Walker S, Hardman TC, Arron JR, Choy DF. A randomized trial of a composite T2-biomarker strategy adjusting corticosteroid treatment in severe asthma: a post hoc analysis by sex. The Journal of Allergy and Clinical Immunology: In Practice. 2023 Apr 1;11(4):1233-42.
11. Rupani H, Kyyaly MA, Azim A, Abadalkareen R, Freeman A, Dennison P, Howarth P, Djukanovic R, Vijayanand P, Seumois G, Arshad SH. Comprehensive characterization of difficult-to-treat asthma reveals near absence of T2-low status. The Journal of Allergy and Clinical Immunology: In Practice. 2023 Sep 1;11(9):2812-21.
12. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients?. Cancer Epidemiology Biomarkers & Prevention. 2006 Feb 1;15(2):194-202.
13. Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Inflammation and Cancer: Methods and Protocols: Volume 1: Experimental Models and Practical Approaches. 2009:159-84.
14. De Robertis M, Greco MR, Cardone RA, Mazza T, Marzano F, Mehterov N, Kazakova M, Belev N, Tullo A, Pesole G, Sarafian V. Upregulation of YKL-40 promotes metastatic phenotype and correlates with poor prognosis and therapy response in patients with colorectal cancer. Cells. 2022 Nov 11;11(22):3568.
15. Johansen JS, Jensen BV, Roslind A, Price PA. Is YKL-40 a new therapeutic target in cancer?. Expert opinion on therapeutic targets. 2007 Feb 1;11(2):219-34.
16. Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. British journal of cancer. 2011 Oct;105(8):1203-9.
17. Colice G, Price D, Gerhardsson de Verdier M, Rabon-Stith K, Ambrose C, Cappell K, Irwin DE, Juneau P, Vlahiotis A. The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship. Pragmatic and observational research. 2017 Dec 1:231-40.
18. Emson C, Pham TH, Manetz S, Newbold P. Periostin and dipeptidyl peptidase-4: potential biomarkers of interleukin 13 pathway activation in asthma and allergy. Immunology and Allergy Clinics. 2018 Nov 1;38(4):611-28.
19. Qu Z, Lu Y, Ran Y, Xu D, Guo Z, Cheng M. Chitinase 3 like protein 1: A potential predictor of cardiovascular disease. Molecular Medicine Reports. 2024 Aug 6;30(4):176.
20. Yu JE, Yeo IJ, Han SB, Yun J, Kim B, Yong YJ, Lim YS, Kim TH, Son DJ, Hong JT. Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer. Experimental & Molecular Medicine. 2024 Jan;56(1):1-8.
21. Zhang L, Li L, Zhou M, Zhou QY, Tang JH, Liang M, Liu Q, Fu XF. Association of serum YKL-40 and DPP4 with T2-high asthma in Chinese adults. Medicine. 2024 Feb 9;103(6):e37169.
22. Zhu Y, Huang B, Jiang G. Correlation between changes in serum YKL-40, LXRs, PPM1A, and TGF-β1 levels and airway remodeling and lung function in patients with bronchial asthma. Journal of Asthma. 2024 Jan 2:1-9.
23. Kim SJ, Choi YJ, Han MY, Hwang IT, Baek HS. Evaluating serum periostin and YKL-40 as biomarkers for airway remodeling and hyperresponsiveness in pediatric asthma. World Allergy Organization Journal. 2024 Nov 1;17(11):100991.
24. Alsharkawy, A.A., Ali, A., Yousef, R.N., Mostafa, D.Y., Zaki, D.A., Monir, R. and Elsheikh, M.S., 2024. Serum YKL-40 as a Potential Diagnostic and Prognostic Biomarker in Asthma: Correlations with Exacerbation, Inflammatory Markers, and Disease Severity. Egyptian Journal of Hospital Medicine, 94(1).
25. Wang YG, Lin C, Huang M, Fang XL, Chen GH, Ye SN. Overexpression of YKL40, IL-6, IL-8, TNF-α in tonsils and the role of YKL40 in childhood with obstructive sleep apnea syndrome. Scientific Reports. 2024 Nov 1;14(1):26283.
26. Liang B, Zhang Y, Ke D, Yan R, Jiang MN, Li L, Zhang LX, Zhao XG, Yuan GP, Xu B, Liu XM. Serum YKL-40 and Serum Krebs von den Lungen-6 as Potential Predictive Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease. Immunological Investigations. 2024 Jun 21:1-2.
27. Lai T, Chen M, Deng Z, Lǚ Y, Wu D, Li D, Wu B. YKL-40 is correlated with FEV 1 and the asthma control test (ACT) in asthmatic patients: influence of treatment. BMC pulmonary medicine. 2015 Dec;15:1-9.
28. Pan R, Li Q, Zhu X, Zhou Y, Ding L, Cui Y. Diagnostic value of YKL-40 for patients with asthma: A meta-analysis. InAllergy and Asthma Proceedings 2021 Nov (Vol. 42, No. 6, p. e167). OceanSide Publications.
29. Jin Y, Song J, Xu F, Zhang D, He J, Zheng J, Zhang Y, Li J, Guo Y, Xu M, Yu X. Association between YKL-40 and asthma: a systematic meta-analysis. Sleep and Breathing. 2022 Sep 1:1-2.
30. Kimura H, Shimizu K, Tanabe N, Makita H, Taniguchi N, Kimura H, Suzuki M, Abe Y, Matsumoto-Sasaki M, Oguma A, Takimoto-Sato M. Further evidence for association of YKL-40 with severe asthma airway remodeling. Annals of Allergy, Asthma & Immunology. 2022 Jun 1;128(6):682-8.
31. Specjalski K, Chełmińska M, Jassem E. YKL-40 protein correlates with the phenotype of asthma. Lung. 2015 Apr;193:189-94.
32. Liu L, Zhang X, Liu Y, Zhang L, Zheng J, Wang J, Hansbro PM, Wang L, Wang G, Hsu AC. Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations. Respiratory Research. 2019 Dec;20:1-2.
33. Gomez JL, Crisafi GM, Holm CT, Meyers DA, Hawkins GA, Bleecker ER, Jarjour N, Investigators SA, Cohn L, Chupp GL. Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40. Journal of Allergy and Clinical Immunology. 2015 Jul 1;136(1):51-8.
34. Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, Radford S, Parry RR, Heinzmann A, Deichmann KA, Lester LA. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. New England Journal of Medicine. 2008 Apr 17;358(16):1682-91.
35. Usemann J, Frey U, Mack I, Schmidt A, Gorlanova O, Röösli M, Hartl D, Latzin P. CHI3L1 polymorphisms, cord blood YKL-40 levels and later asthma development. BMC pulmonary medicine. 2016 Dec;16:1-9.
36. Specjalski K, Romantowski J, Niedoszytko M. YKL-40 as a possible marker of neutrophilic asthma. Frontiers in Medicine. 2023 Feb 8;10:1115938.
37. Rathcke CN, Holmkvist J, Husmoen LL, Hansen T, Pedersen O, Vestergaard H, Linneberg A. Association of polymorphisms of the CHI3L1 gene with asthma and atopy: a populations-based study of 6514 Danish adults. PLoS One. 2009 Jul 1;4(7):e6106.
38. Kanazawa J, Kitazawa H, Masuko H, Yatagai Y, Sakamoto T, Kaneko Y, Iijima H, Naito T, Saito T, Noguchi E, Konno S. A cis-eQTL allele regulating reduced expression of CHI3L1 is associated with late-onset adult asthma in Japanese cohorts. BMC Medical Genetics. 2019 Dec;20:1-0.
39. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Current medicinal chemistry. 2009 Aug 1;16(23):2943-51.
40. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocrine reviews. 2014 Dec 1;35(6):992-1019.
41. Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci. 2008 May 1;13(13):3648-60.
42. Omar BA, Liehua L, Yamada Y, Seino Y, Marchetti P, Ahrén B. Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia. 2014 Sep;57:1876-83.
43. Tasic T, Stephan M, von Hörsten S, Pabst R, Schmiedl A. Differential OVA-induced pulmonary inflammation and unspecific reaction in Dark Agouti (DA) rats contingent on CD26/DPPIV deficiency. Immunobiology. 2014 Nov 1;219(11):888-900.
44. Vázquez‐Mera S, Martelo‐Vidal L, Miguéns‐Suárez P, Bravo SB, Saavedra‐Nieves P, Arias P, Ferreiro‐Posse A, Vázquez‐Lago J, Salgado FJ, González‐Barcala FJ, Nieto‐Fontarigo JJ. Exploring CD26−/lo subpopulations of lymphocytes in asthma phenotype and severity: A novel CD4+ T cell subset expressing archetypical granulocyte proteins. Allergy. 2024 Sep 25.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |